Hetero launches the biosimilar ‘Adalimumab’ under the brand name ‘Mabura’ in India

India, Hyderabad, 3rd January 2018: Hetero, one of India’s leading generic pharmaceutical companies and the world’s largest producer of anti-retroviral drugs, today announces the launch of its fourth biosimilar drug ‘Adalimumab’ under the brand name ‘Mabura TM’ in India. The product will be marketed and distributed by Hetero Healthcare in the country.

Mabura TM is an anti-inflammatory biologic medication specific for human tumor necrosis factor (TNF), indicated for the treatment of rheumatoid arthritis and other auto-immune disorders such as psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis etc. Mabura TM will be available as a pre-filled syringe (PFS) of 40mg and is administered subcutaneously.

Hetero’s Mabura TM is the Biosimilar version of AbbVie’s HumiraTM. Adalimumab is the first fully human monoclonal antibody which was first approved by US FDA in 2002.

The product will be manufactured at our dedicated state-of-the-art manufacturing facility for Biologics, based at Hyderabad, India.